Therapies for Children With Autism Spectrum Disorders

1008. Ferri R, Elia M, Agarwal N, et al. The mismatch negativity and the P3a components of
the auditory event-related potentials in autistic low-functioning subjects. Clin
Neurophysiol. 2003 Sep;114(9):1671-80. X-4
1009. Fertel-Daly D, Bedell G and Hinojosa J. Effects of a weighted vest on attention to task
and self-stimulatory behaviors in preschoolers with pervasive developmental disorders.
Am J Occup Ther. 2001 Nov-Dec;55(6):629-40. X-3
1010. Fido A and Al-Saad S. Olanzapine in the treatment of behavioral problems associated
with autism: an open-label trial in Kuwait. Med Princ Pract. 2008;17(5):415-8. X-1, X-3
1011. Field T, Lasko D, Mundy P, et al. Brief report: autistic children’s attentiveness and
responsivity improve after touch therapy. J Autism Dev Disord. 1997 Jun;27(3):333-8. X-
10
1012. Fienup DM and Doepke K. Evaluation of a Changing Criterion Intervention to Increase
Fluent Responding with an Elementary Age Student with Autism. International Journal of
Behavioral Consultation and Therapy. 2008;4(3):297-303. X-3
1013. Filipo R, Bosco E, Mancini P, et al. Cochlear implants in special cases: deafness in the
presence of disabilities and/or associated problems. Acta Otolaryngol Suppl. 2004
May(552):74-80. X-1, X-3, X-4
1014. Findling RL. Paediatric psychopharmacology: closing the gap between science and
practice. Expert Opin Pharmacother. 2001 Apr;2(4):523-5. X-1, X-2, X-3
1015. Findling RL. Pharmacologic treatment of behavioral symptoms in autism and pervasive
developmental disorders. J Clin Psychiatry. 2005;66 Suppl 10:26-31. X-1, X-2, X-3, X-4
1016. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone
in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry.
2004 Apr;161(4):677-84. X-1
1017. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of
aripiprazole in children and adolescents with psychiatric disorders: an open-label, doseescalation
study. J Clin Psychopharmacol. 2008 Aug;28(4):441-6. X-1, X-3, X-4
1018. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term
risperidone treatment in children and adolescents. J Clin Psychiatry. 2003
Nov;64(11):1362-9. X-1, X-4
1019. Findling RL, Maxwell K, Scotese-Wojtila L, et al. High-dose pyridoxine and magnesium
administration in children with autistic disorder: an absence of salutary effects in a
double-blind, placebo-controlled study. J Autism Dev Disord. 1997 Aug;27(4):467-78.
X-10
1020. Findling RL, Maxwell K and Wiznitzer M. An open clinical trial of risperidone
monotherapy in young children with autistic disorder. Psychopharmacol Bull.
1997;33(1):155-9. X-3, X-10
1021. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of
risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry.
2000 Apr;39(4):509-16. X-1, X-3, X-4
D-71